Envestnet Asset Management Inc. Raises Stock Position in Medtronic PLC $MDT

Envestnet Asset Management Inc. increased its holdings in shares of Medtronic PLC (NYSE:MDT) by 5.0% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 5,694,827 shares of the medical technology company’s stock after purchasing an additional 272,938 shares during the quarter. Envestnet Asset Management Inc. owned approximately 0.44% of Medtronic worth $542,375,000 at the end of the most recent reporting period.

Other large investors also recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its holdings in shares of Medtronic by 1.5% in the second quarter. Vanguard Group Inc. now owns 126,909,406 shares of the medical technology company’s stock worth $11,062,693,000 after purchasing an additional 1,895,165 shares during the last quarter. Geode Capital Management LLC grew its holdings in Medtronic by 1.1% during the 2nd quarter. Geode Capital Management LLC now owns 28,227,006 shares of the medical technology company’s stock valued at $2,448,699,000 after buying an additional 310,684 shares in the last quarter. Bank of New York Mellon Corp grew its holdings in Medtronic by 0.9% during the 3rd quarter. Bank of New York Mellon Corp now owns 21,468,260 shares of the medical technology company’s stock valued at $2,044,637,000 after buying an additional 192,410 shares in the last quarter. Massachusetts Financial Services Co. MA increased its stake in Medtronic by 0.5% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 21,086,499 shares of the medical technology company’s stock worth $2,008,278,000 after acquiring an additional 98,220 shares during the last quarter. Finally, Invesco Ltd. raised its holdings in shares of Medtronic by 3.9% during the 2nd quarter. Invesco Ltd. now owns 17,647,149 shares of the medical technology company’s stock worth $1,538,302,000 after acquiring an additional 666,557 shares in the last quarter. 82.06% of the stock is owned by hedge funds and other institutional investors.

Medtronic Trading Up 0.5%

Shares of NYSE MDT opened at $103.21 on Wednesday. Medtronic PLC has a fifty-two week low of $79.55 and a fifty-two week high of $106.33. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.80 and a current ratio of 2.42. The company has a market cap of $132.31 billion, a price-to-earnings ratio of 27.82, a PEG ratio of 2.71 and a beta of 0.71. The business’s 50 day moving average price is $99.55 and its 200-day moving average price is $95.92.

Medtronic (NYSE:MDT) last announced its quarterly earnings data on Tuesday, November 18th. The medical technology company reported $1.36 EPS for the quarter, beating the consensus estimate of $1.31 by $0.05. Medtronic had a return on equity of 14.86% and a net margin of 13.71%.The company had revenue of $8.96 billion for the quarter, compared to the consensus estimate of $8.86 billion. During the same quarter in the prior year, the company posted $1.26 EPS. Medtronic’s quarterly revenue was up 6.6% on a year-over-year basis. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. On average, sell-side analysts expect that Medtronic PLC will post 5.46 earnings per share for the current year.

Medtronic Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, January 16th. Shareholders of record on Friday, December 26th were given a dividend of $0.71 per share. The ex-dividend date of this dividend was Friday, December 26th. This represents a $2.84 dividend on an annualized basis and a yield of 2.8%. Medtronic’s payout ratio is 76.55%.

Analyst Upgrades and Downgrades

MDT has been the subject of a number of recent research reports. Jefferies Financial Group reissued a “hold” rating and issued a $110.00 target price on shares of Medtronic in a report on Wednesday, November 19th. The Goldman Sachs Group set a $111.00 price objective on shares of Medtronic and gave the stock a “neutral” rating in a research note on Wednesday, November 19th. Weiss Ratings reissued a “buy (b-)” rating on shares of Medtronic in a research note on Monday, December 29th. JPMorgan Chase & Co. raised their price objective on Medtronic from $90.00 to $100.00 and gave the company a “neutral” rating in a research note on Thursday, November 13th. Finally, Stifel Nicolaus lifted their target price on Medtronic from $90.00 to $105.00 and gave the stock a “hold” rating in a report on Thursday, October 9th. Fifteen analysts have rated the stock with a Buy rating and eleven have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $110.56.

Key Medtronic News

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Medtronic will acquire CathWorks for up to $585 million, adding the CathWorks FFRangio® diagnostic system and broader AI-enabled heart-imaging capabilities to its cath-lab portfolio — a strategic bolt-on to accelerate growth in interventional cardiology and digital heart care. Medical device maker Medtronic to buy CathWorks in up to $585 million deal
• Positive Sentiment: Medtronic highlights the acquisition as advancing its innovation strategy and follows an existing 2022 strategic partnership/co-promotion — signaling faster commercialization and lower early-stage integration risk than a greenfield deal. Medtronic advances its innovation strategy with intent to acquire CathWorks
• Positive Sentiment: Medtronic Diabetes secured Medicare access and new FDA clearances for the MiniMed 780G system (including use with ultra‑rapid‑acting insulins and for insulin‑requiring type 2 diabetes), expanding addressable market and reimbursement coverage. Medtronic Diabetes expands access to full-stack insulin delivery solutions with Medicare access and new FDA clearances
• Positive Sentiment: New analyst coverage is bullish: Citigroup initiated coverage with a Buy and $117 price target (~13% upside from current levels), which can attract buyers and support multiple expansion. (Coverage note from brokerage reports)
• Neutral Sentiment: Wells Fargo also started research coverage on MDT, broadening institutional attention but not yet translating into a consensus rating change. Medtronic (NYSE:MDT) Research Coverage Started at Wells Fargo & Company
• Neutral Sentiment: Industry commentary notes that Wall Street remains moderately optimistic on MDT despite recent underperformance versus the S&P 500 — sentiment supportive but not catalytic. Are Wall Street Analysts Predicting Medtronic Stock Will Climb or Sink?
• Negative Sentiment: Deal risks: the acquisition is subject to U.S. regulatory approval and integration/execution risk; investors should watch regulatory milestones and any contingent payments up to $585M that could affect near-term cash flow. Medtronic Bets On AI Heart Care With $585 Million Deal For Partner CathWorks

Medtronic Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).